Loading company…
Ossianix, Inc. of Philadelphia develops TXP1 Brain Shuttle technology to deliver biologics across the blood-brain barrier.
Founded in 2011 and headquartered in Philadelphia, US, Ossianix, Inc. was co-founded by Frank Walsh and Lynn Rutkowski. Its TXP1 Brain Shuttle uses a deimmunised VNAR antibody scaffold that targets the transferrin receptor 1 to carry therapeutics into the central nervous system, for pharmaceutical partners. The company has completed three deals, the most recent on October 24, 2014, with venture funding from BioAdvance Ventures in an undisclosed amount.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in